Following its approval in the UK, Hansoh Pharmaceutical's aumolertinib has achieved another milestone with its Phase II ACHIEVE study data on high-dose treatment for non-small cell lung cancer (NSCLC) brain metastases published in JAMA Oncology. The study reported an impressive intracranial objective response rate (iORR) of 82.5%, positioning aumolertinib as a leading third-generation EGFR tyrosine kinase inhibitor (TKI). This breakthrough addresses a critical unmet need, as NSCLC patients with brain metastases face limited treatment options and poor survival rates.

Aumolertinib, China's first domestically developed third-generation EGFR-TKI, has expanded its clinical applications from first-line therapy to maintenance and adjuvant treatment. Its success in tackling brain metastases — a notoriously difficult-to-treat condition — further solidifies its role as a cornerstone therapy in NSCLC. With ongoing trials exploring combinations with EGFR/c-Met bispecific antibodies (BsAbs) and c-Met inhibitors, aumolertinib aims to overcome resistance and extend its global reach, having already secured approval in the UK and progressing toward EU submission.

According to PharmCube's NextBiopharm® database, globally there exist only 6 similarly acting EGFR T790M inhibitors for brain metastasis (image below), only two of which originate outside China. Click here to request a free trial for NextBiopharm®.

Source:
https://jamanetwork.com/journals/jamaoncology/fullarticle/2835817